Fulcrum Therapeutics (FULC) Operating Expenses (2018 - 2026)
Fulcrum Therapeutics (FULC) posted quarterly Operating Expenses of $29.3 million for Q2 2026, up 47.92% year-over-year from $19.8 million in Q2 2025, and up 32.11% quarter-over-quarter from $22.2 million in Q1 2026.
Fulcrum Therapeutics (FULC) Operating Expenses (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported Operating Expenses for 9 consecutive years, with $29.3 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Operating Expenses rose 47.92% year-over-year to $29.3 million; the TTM figure through Jun 2026 stood at $96.0 million (up 13.3% YoY), while the FY2025 annual figure was $84.8 million, down 16.81% from the prior year.
- Operating Expenses advanced to $29.3 million in Q2 2026 per FULC's latest filing, from $22.2 million in the prior quarter.
- Across five years, Operating Expenses topped out at $36.1 million in Q2 2022 and bottomed at $19.4 million in Q4 2024.
- Historically, Operating Expenses has averaged $26.1 million across 5 years, with a median of $27.8 million in 2023.
- Annual changes were most pronounced in 2022 — Operating Expenses surged 50.09% — and 2024, when it slumped 32.69%.
- Fulcrum Therapeutics' Operating Expenses stood at $28.7 million in 2022, then rose by 0.72% to $28.9 million in 2023, then tumbled by 32.69% to $19.4 million in 2024, then gained by 16.8% to $22.7 million in 2025, then increased by 29.16% to $29.3 million in 2026.
- Business Quant data shows FULC's Operating Expenses at $29.3 million in Q2 2026, $22.2 million in Q1 2026, and $22.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Fulcrum Therapeutics | 285.31 Mn | 285.31 Mn | - | 29.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.31 Mn |
| Mar 31, 2026 | 22.19 Mn |
| Dec 31, 2025 | 22.69 Mn |
| Sep 30, 2025 | 21.86 Mn |
| Jun 30, 2025 | 19.82 Mn |
| Mar 31, 2025 | 20.40 Mn |
| Dec 31, 2024 | 19.43 Mn |
| Sep 30, 2024 | 25.13 Mn |
| Jun 30, 2024 | 27.51 Mn |
| Mar 31, 2024 | 29.83 Mn |
| Dec 31, 2023 | 28.86 Mn |
| Sep 30, 2023 | 28.20 Mn |
| Jun 30, 2023 | 28.17 Mn |
| Mar 31, 2023 | 28.24 Mn |
| Dec 31, 2022 | 28.66 Mn |
| Sep 30, 2022 | 25.54 Mn |
| Jun 30, 2022 | 36.12 Mn |
| Mar 31, 2022 | 28.59 Mn |
| Dec 31, 2021 | 28.62 Mn |
| Sep 30, 2021 | 25.71 Mn |